Heart and Vessels

, Volume 30, Issue 4, pp 545–548 | Cite as

Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases

  • Hee Hwa Ho
  • Min Er Ching
  • Paul Jau Lueng Ong
  • Yau Wei Ooi
Case Report


Drug-eluting bioresorbable vascular scaffold (BVS) is a revolutionary treatment option for obstructive coronary artery disease in percutaneous coronary intervention. It restores blood flow to the myocardium but unlike permanent metallic stent, BVS dissolves in the body within 2 years. This allows the coronary vessel to regain its normal function and motion. The clinical efficacy and safety of BVS in the first-in-human trials have been reported with low major adverse cardiac event rates observed at short- and long-term follow-up. The incidence of BVS scaffold thrombosis (ST) in these studies was 0 %. There is limited data on the incidence of BVS ST in the real world. We report 2 cases of subacute ST involving BVS in our real-world practice and discuss on the possible mechanisms of these thrombotic episodes (with insights from intracoronary imaging studies).


Bioresorbable Scaffold Thrombosis Vascular 


Conflict of interest

The authors report no conflicts of interest.


  1. 1.
    Brugaletta S, Garcia-Garcia HM, Onuma Y, Serruys PW (2012) Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives. Expert Rev Med Devices 9(4):327–338PubMedCrossRefGoogle Scholar
  2. 2.
    Costopoulos C, Naganuma T, Latib A, Colombo A (2013) Looking into the future with bioresorbable vascular scaffolds. Expert Rev Cardiovasc Ther 11(10):1407–1416PubMedCrossRefGoogle Scholar
  3. 3.
    Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia-Garcia HM, Ormiston JA, Serruys PW (2013) Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv 6(10):999–1009PubMedCrossRefGoogle Scholar
  4. 4.
    Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA (2011) Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 58(15):1578–1588PubMedCrossRefGoogle Scholar
  5. 5.
    Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A (2005) Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130PubMedCrossRefGoogle Scholar
  6. 6.
    Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115:1051–1058PubMedCrossRefGoogle Scholar
  7. 7.
    Ito D, Shiraishi J, Nakamura T, Maruyama N, Iwamura Y, Hashimoto S, Kimura M, Matsui A, Yokoi H, Arihara M, Irie H, Hyogo M, Shima T, Kohno Y, Matsumuro A, Sawada T, Matsubara H (2012) Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy. Heart Vessels 27(6):634–638PubMedCrossRefGoogle Scholar
  8. 8.
    Arima M, Matsuda A, Nitta M, Yoshida K, Shimizu M (2012) A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. Heart Vessels 27(1):106–109PubMedCrossRefGoogle Scholar
  9. 9.
    Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia H, Ormiston JA, ABSORB Cohort A and B investigators (2011) Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 78(1):3–12PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  • Hee Hwa Ho
    • 1
  • Min Er Ching
    • 1
  • Paul Jau Lueng Ong
    • 1
  • Yau Wei Ooi
    • 1
  1. 1.Department of CardiologyTan Tock Seng HospitalSingaporeSingapore

Personalised recommendations